| Literature DB >> 32224121 |
Ryan Choi1, Matthew A Hulverson1, Wenlin Huang2, Rama S R Vidadala3, Grant R Whitman1, Lynn K Barrett1, Deborah A Schaefer4, Dana P Betzer4, Michael W Riggs4, J Stone Doggett5, Andrew Hemphill6, Luis Miguel Ortega-Mora7, Molly C McCloskey1, Samuel L M Arnold1, Robert C Hackman8, Kennan C Marsh9, James J Lynch9, Gail M Freiberg9, Bruce E Leroy9, Dale J Kempf9, Robert K M Choy10, Eugenio L de Hostos10, Dustin J Maly3, Erkang Fan2, Kayode K Ojo1, Wesley C Van Voorhis11.
Abstract
Bumped Kinase Inhibitors, targeting Calcium-dependent Protein Kinase 1 in apicomplexan parasites with a glycine gatekeeper, are promising new therapeutics for apicomplexan diseases. Here we will review advances, as well as challenges and lessons learned regarding efficacy, safety, and pharmacology that have shaped our selection of pre-clinical candidates.Entities:
Keywords: Apicomplexa; Bumped Kinase Inhibitor; Calcium-dependent Protein Kinases; Cryptosporidium; Gatekeeper; Neospora; Sarcocystis; Toxoplasma
Mesh:
Substances:
Year: 2020 PMID: 32224121 DOI: 10.1016/j.ijpara.2020.01.006
Source DB: PubMed Journal: Int J Parasitol ISSN: 0020-7519 Impact factor: 3.981